Cti Biopharma Co (CTIC)


Cell Therapeut develops, acquires and commercializes novel treatments for cancer. It markets TRISENOX (arsenic trioxide) for the treatment of relapsed or refractory acute promyelocytic leukemia, or APL, in the U.S. and the European Union.

View SEC Filings from CTIC instead.
Filers who had this stock in their top 10: 0
13F Filers holding this stock: 62
Aggregate shares on 09/30/2016: 71,237,007
Aggregate shares on 06/30/2016: 81,882,657
Percent change: -13.00%
Funds creating new positions: 8
Funds Adding to an existing position: 9
Funds closing out their position: 13
Funds reducing their position: 23
View recent insider trading info

13F Filers holding this stock

Quarter 1: Refresh

Changes in Holdings:

*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Schedule 13D and 13G filings submitted since 09/30/2016

Subscription required

Click here to report any possible errors with this stock listing.

Elevate your investments

or Learn more